Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Vivoryon Therapeutics NV's Goodwill for the quarter that ended in Jun. 2026 was €0.00 Mil. Vivoryon Therapeutics NV's Total Assets for the quarter that ended in Jun. 2026 was €4.17 Mil.
If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.
Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.
Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.
Vivoryon Therapeutics NV Goodwill-to-Asset Related Terms
Vivoryon Therapeutics NV Goodwill-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:VVYN vs VRTX, REGN, MRNA: Goodwill-to-Asset Comparison
For the Biotechnology subindustry, Vivoryon Therapeutics NV's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivoryon Therapeutics NV Goodwill-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vivoryon Therapeutics NV's Goodwill-to-Asset distribution charts can be found below:
* The bar in red indicates where Vivoryon Therapeutics NV's Goodwill-to-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vivoryon Therapeutics NV (WBO:VVYN) has a Goodwill-to-Asset of 0.00 as of Jun. 2026. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Goodwill-to-Asset too high?
Vivoryon Therapeutics NV's current Goodwill-to-Asset is 0.00. Overall, Vivoryon Therapeutics NV has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Goodwill-to-Asset compare to VRTX and REGN?
Vivoryon Therapeutics NV's Goodwill-to-Asset of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Goodwill-to-Asset for a Biotechnology company?
A good Goodwill-to-Asset depends on the Biotechnology industry context. However, Goodwill-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Goodwill-to-Asset mean?
A high Goodwill-to-Asset can signal that a stock is expensive relative to its fundamentals. Goodwill-to-Asset Ratio is the total goodwill from acquisitions divided by total assets. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Goodwill-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current Goodwill-to-Asset of 0.00. The current Goodwill-to-Asset is 0.00. Vivoryon Therapeutics NV's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Goodwill-to-Asset calculated?
Goodwill-to-Asset is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current Goodwill-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
15GF Score
Get the complete analysis for WBO:VVYN
Goodwill-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:VVYN has been successfully added to your 
